ライフサイエンスコーパス: DNA gyrase

1 laxing enzyme (eukaryotic topoisomerase I or DNA gyrase).

2 ugh validated drug targets such as bacterial DNA gyrase.

3 itors of the bacterial type II topoisomerase DNA gyrase.

4 ition of the bacterial type-II topoisomerase DNA gyrase.

5 otics and is a well-established inhibitor of DNA gyrase.

6 emic negative supercoil energy introduced by DNA gyrase.

7 is the pharmacophore for targeting bacterial DNA gyrase.

8 at minimally contained T7 RNA polymerase and DNA gyrase.

9 cent of those seen in structures of MutL and DNA gyrase.

10 h are the putative target binding motifs for DNA gyrase.

11 coumermycin A1, an antibiotic that inhibits DNA gyrase.

12 t interacts with the target bacterial enzyme DNA gyrase.

13 e; the putative target of this antibiotic is DNA gyrase.

14 for clinically useful antibiotics that block DNA gyrase.

15 a interaction with the type II topoisomerase DNA gyrase.

16 elated to the ATP-binding motif of bacterial DNA gyrase.

17 the spirochete and functions as a subunit of DNA gyrase.

18 l environment via changes in the activity of DNA gyrase.

19 CcdB is a bacterial toxin that targets DNA gyrase.

20 ed within the gene encoding the A subunit of DNA gyrase.

21 to that of an ATPase-containing fragment of DNA gyrase.

22 r protein CcdB with its intracellular target DNA gyrase.

23 ts and were found to be potent inhibitors of DNA gyrase.

24 the amino acid sequence of the A subunit of DNA gyrase.

25 in mapped in gyrB, one of the genes encoding DNA gyrase.

26 e quinolone group of antibacterial agents is DNA gyrase.

27 lly modified peptide that inhibits bacterial DNA gyrase.

28 rs, consistent with allosteric inhibition of DNA gyrase.

29 ed by Streptomyces antibioticus that targets DNA gyrase.

30 Against Gram-negative microorganisms and DNA gyrase a preference for S-absolute configuration was

31 complexed with the N-terminal domain of the DNA gyrase A protein (GyrA) suggested that four SD8 mole

32 rial agents that act by inhibiting bacterial DNA gyrase, a target of clinical significance.

33 umermycin, which are classical inhibitors of DNA gyrase, a type II enzyme.

34 d in terms of current mechanistic models for DNA gyrase action and the possible in vivo roles of the

35 ion, the reaction selectivity for a model of DNA gyrase action that assumes existence of a free loop

36 yrI (also called sbmC) gene product inhibits DNA gyrase activity in vitro, while the rob protein appe

37 fective for the DNA relaxation activity, and DNA gyrase activity is reduced; second, the suppressor p

38 chemical network) resulting in inhibition of DNA gyrase activity, the primary target of fluoroquinolo

39 hthyridones that kills Mtb by inhibiting the DNA gyrase activity.

40 DNA gyrases also bind to DNA at the non-homologous C-ter

41 hich we detected catenation was 50-60 bp for DNA gyrase and 40 bp for topoisomerase IV (Topo IV).

42 d both inhibit bacterial growth by attacking DNA gyrase and by stimulating enzyme-induced breaks in b

43 omal gyrB gene that encodes the B subunit of DNA gyrase and confers resistance to the antibiotic coum

44 cdB can stabilise a cleavage complex between DNA gyrase and DNA in a manner distinct from quinolones

45 ssaying DNA supercoiling by Escherichia coli DNA gyrase and DNA relaxation by eukaryotic topoisomeras

46 agent in complex with Staphylococcus aureus DNA gyrase and DNA, showing a new mode of inhibition tha

47 y and explains both its inhibitory effect on DNA gyrase and fluoroquinolone resistance resulting from

48 nds were tested for their ability to inhibit DNA gyrase and found to exhibit significant reduction in

49 d not show significant inhibition of E. coli DNA gyrase and hTop 1 even up to 100 muM.

50 f the bgl operon occur in the genes encoding DNA gyrase and in the gene encoding the nucleoid associa

51 the antibiotic fluoroquinolone by binding to DNA gyrase and inhibiting its activity.

52 MfpA binds to DNA gyrase and inhibits its activity.

53 This protein binds to DNA gyrase and inhibits its activity.

54 as a molecular 'clamp' mechanism, similar to DNA gyrase and MutL, whose opening and closing by transi

55 throughput microtitre plate-based assays for DNA gyrase and other DNA topoisomerases.

56 h rate but bind to different target enzymes (DNA gyrase and penicillin-binding proteins, respectively

57 How Qnr protects DNA gyrase and the prevalence of this resistance mechani

58 the toxin CcdB prevents CcdB from inhibiting DNA gyrase and thereby averts cell death.

59 Rare temperature-sensitive alleles of DNA gyrase and Topo IV (the two essential type II topois

60 acteria possess two type IIA topoisomerases, DNA gyrase and topo IV, that together help manage chromo

61 ts provide a physiologic distinction between DNA gyrase and topo IV.

62 f unlinking of various topoisomers of DNA by DNA gyrase and Topo IV.

63 Quinolone antimicrobial drugs target both DNA gyrase and topoisomerase IV (Topo IV) and convert th

64 DNA gyrase and topoisomerase IV (Topo IV) are cellular t

65 DNA gyrase and topoisomerase IV (Topo IV) are type II ba

66 DNA gyrase and topoisomerase IV (Topo IV) have distinct

67 We found that both DNA gyrase and topoisomerase IV (topo IV) promote replic

68 In bacteria, DNA gyrase and topoisomerase IV act ahead of the fork to

69 YejK interacts with all the subunits of both DNA gyrase and topoisomerase IV and has measurable effec

70 /ParE ATP-binding sites located on bacterial DNA gyrase and topoisomerase IV and not utilized by mark

71 Bacterial DNA gyrase and topoisomerase IV are essential enzymes th

72 Bacterial DNA gyrase and topoisomerase IV are well-characterized c

73 DNA gyrase and topoisomerase IV control bacterial DNA to

74 Bacterial DNA gyrase and topoisomerase IV control the topological

75 improved inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV from both bacteria.

76 mpound 27 was the most balanced inhibitor of DNA gyrase and topoisomerase IV from both E. coli and S.

77 Inhibition of the topoisomerases DNA gyrase and topoisomerase IV from both Gram-positive

78 nolone antibiotics otherwise known to target DNA gyrase and topoisomerase IV in bacterial cells.

79 rahydropyran-based molecules that are potent DNA gyrase and topoisomerase IV inhibitors and display e

80 for structure-based optimization toward dual DNA gyrase and topoisomerase IV inhibitors with antibact

81 this class of compounds toward balanced dual DNA gyrase and topoisomerase IV inhibitors with antibact

82 nolones are antibacterial agents that attack DNA gyrase and topoisomerase IV on chromosomal DNA.

83 ibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) are of interest for the

84 ibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) display potent activity

85 ibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) display potent antibact

86 ibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) have the potential to b

87 n of a new class of bacterial topoisomerase (DNA gyrase and topoisomerase IV) inhibitors binding in t

88 organisms, (b) inhibitory activities against DNA gyrase and topoisomerase IV, and (c) no inhibitory a

89 floxacin, inhibit the type 2 topoisomerases, DNA gyrase and topoisomerase IV, and can cleave DNA at s

90 ch as 6 and 21 are potent inhibitors of both DNA gyrase and topoisomerase IV, displaying antibacteria

91 rong inhibitory activities against S. aureus DNA gyrase and topoisomerase IV, with weak activity agai

92 al agents that specifically target bacterial DNA gyrase and topoisomerase IV.

93 unds against the ATP binding pockets of both DNA gyrase and topoisomerase IV.

94 cessivity of the DNA helicase might overcome DNA gyrase and topoisomerase IV.

95 nhibitors that bind to the catalytic site of DNA gyrase and topoisomerase IV.

96 ary phase, whereas during exponential growth DNA gyrase and/or transcription equalizes supercoiling a

97 t bacterial type II DNA topoisomerases (e.g. DNA gyrase) and are among the most important antibiotics

98 related with excess negative supercoiling by DNA gyrase, and the gyrase inhibitor, coumermycin, rever

99 to ofloxacin, a fluoroquinolone inhibitor of DNA gyrase, and to topoisomerase IV and were almost comp

100 antibiotics novobiocin and clorobiocin with DNA gyrase are illustrative of the importance of bound w

101 Topoisomerase I and DNA gyrase are the major topoisomerase activities respon

102 Fluoroquinolone antibacterials, which target DNA gyrase, are critical agents used to halt the progres

103 Members of one class of the enzymes, DNA gyrases, are configured to carry out an intramolecul

104 cterial agents that operate by inhibition of DNA gyrase as corroborated in an enzyme assay and by the

105 originally annotated as potentially encoding DNA gyrase: ATGYRA, ATGYRB1, ATGYRB2, and ATGYRB3.

106 reveal unique features of the S. pneumoniae DNA gyrase ATPase and demonstrate the utility of the ass

107 rcular activity acting through inhibition of DNA Gyrase B (GyrB) ATPase.

108 ever, inhibitors of its ATP binding subunit, DNA gyrase B (GyrB), have so far not reached clinical us

109 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole-based DNA gyrase B inhibitors, we replaced their central core

110 ides were designed and prepared as potential DNA gyrase B inhibitors.

111 further optimization of this novel class of DNA gyrase B inhibitors.

112 cture of the 43 kDa N-terminal domain of the DNA gyrase B protein (GyrB) shows that the majority of t

113 Glu in the highly conserved QTK-loop in the DNA gyrase B protein homologous domain of Drosophila top

114 We have examined the role of the DNA gyrase B protein in cleavage and religation of DNA u

115 N-terminal fragment of the Escherichia coli DNA gyrase B protein in complexes with two different inh

116 ure of the 43 kDa N-terminal fragment of the DNA gyrase B protein shows a large cavity within the pro

117 -oxoacetic acid (24) in complex with E. coli DNA gyrase B revealed the binding mode of the inhibitor

118 on crystal structure in complex with E. coli DNA gyrase B was obtained, revealing details of its bind

119 Using information on a related ATPase, DNA gyrase B, we selected three conserved residues in hs

120 ow micromolar inhibitors of Escherichia coli DNA gyrase based on the 5,6,7,8-tetrahydroquinazoline an

121 se catenated molecules become supercoiled by DNA gyrase before they undergo a complete decatenation b

122 nt) sequence of the Treponema denticola (Td) DNA gyrase beta-subunit gene (gyrB) has been determined.

123 elegans homologues of pyruvate carboxylase, DNA gyrase, beta-adrenergic receptor kinase, and human h

124 impart the noviose decorations required for DNA gyrase binding and antibiotic activity.

125 A strong DNA gyrase-binding site (SGS) is located midway between

126 atalytic domain across the DNA gate, whereas DNA gyrase binds to DNA not only at the amino-terminal c

127 te sites was cleaved specifically by E. coli DNA gyrase both in vitro and in vivo.

128 dB that fail to bind to its cellular target, DNA gyrase, but retain binding to the antitoxin, CcdA.

129 660/661 have been predicted to form a second DNA gyrase, but the reconstitute holoenzyme decatenated

130 is an orally active antibiotic that inhibits DNA gyrase by binding the ATP-binding site in the ATPase

131 mutants, second, the specific inhibition of DNA gyrase by novobiocin, and third, the genetic removal

132 and coumermycin A(1) target the B subunit of DNA gyrase by presentation of the 5-methyl-pyrrolyl-2-ca

133 unctional antibiotics that inhibit bacterial DNA gyrase by preventing DNA binding to the enzyme.

134 re broad-spectrum antibacterials that target DNA gyrase by stabilizing DNA-cleavage complexes, but th

135 ported specific labeling of Escherichia coli DNA gyrase by the ATP affinity analog pyridoxal 5'-dipho

136 MccB17 inhibits its cellular target, DNA gyrase, by trapping the enzyme in a complex that is

137 imidodiphosphate (ADPNP) to Escherichia coli DNA gyrase can lead to a limited noncatalytic supercoili

138 DNA gyrase catalyses DNA supercoiling by passing one seg

139 DNA gyrase catalyzes ATP-dependent negative supercoiling

140 action, the crystal structures of the WT Mtb DNA gyrase cleavage core and a fluoroquinolone-sensitize

141 s, targeted the GyrA subunit and stalled the DNA-gyrase cleavage complex.

142 Analysis of multiple DNA gyrase co-crystal structures, including asymmetric c

143 at inhibition occurs specifically at the DNA-DNA gyrase complex and is not attributable to nonspecifi

144 ic acid monohydroxamides can bind to the DNA-DNA gyrase complex in a similar fashion as that hypothes

145 Covalent topoisomerase I and DNA gyrase complexes are converted into double-strand br

146 rentiate between the C-terminus of Hsp90 and DNA gyrase, converted a well-established gyrase inhibito

147 X-ray crystallography of DNA gyrase-DNA complexes shows the compounds binding to

148 wo indispensable type II DNA topoisomerases, DNA gyrase encoded by gyrB and gyrA and topoisomerase IV

149 However, E. coli DNA gyrase essentially failed to negatively supercoil 35

150 sulted in equipotent nanomolar inhibitors of DNA gyrase from Escherichia coli displaying improved inh

151 The IC50 values of compounds on DNA gyrase from Escherichia coli were in the low micromo

152 rified Qnr-His(6) protected Escherichia coli DNA gyrase from inhibition by ciprofloxacin.

153 hat both contribute to protection of E. coli DNA gyrase from quinolones.

154 compounds, the inhibitory activities against DNA gyrase from Staphylococcus aureus and topoisomerases

155 ty protein McbG, which is thought to protect DNA gyrase from the action of microcin B17.

156 ication of a 176-base pair fragment from the DNA gyrase gene of Neisseria gonorrhoeae was performed a

157 Quinolone antibacterial drugs target both DNA gyrase (Gyr) and topoisomerase IV (Topo IV) and form

158 The ability of DNA gyrase (Gyr) to wrap the DNA strand around itself al

159 Sequencing of the gene encoding subunit A of DNA gyrase (gyrA) revealed a mutation associated with fl

160 ta subunits of the RNA polymerase (RpoB) and DNA gyrase (GyrB) and with the 16S rRNA-based phylogeny.

161 The B subunit of DNA gyrase (GyrB) consists of a 43 kDa N-terminal domain

162 Likewise, inhibition of DNA gyrase had no detectable effect on Erp expression.

163 of drug-DNA interaction in the A subunit of DNA gyrase has previously been identified from crystallo

164 Earlier results, however, indicated that DNA gyrase has the primary role in unlinking the catenat

165 ocoumarin antibiotics, compounds that target DNA gyrase in bacteria.

166 acterial drugs such as nalidixic acid target DNA gyrase in Escherichia coli.

167 ecting the interactions of Qnr proteins with DNA gyrase in gram-negative bacteria.

168 Because the primary target of quinolones is DNA gyrase in Gram-negative strains, we tested the abili

169 are excellent targets for chemotherapy, and DNA gyrase in particular is a well-validated target for

170 ecomes more sensitive to the level of active DNA gyrase in the cell.

171 e establish by genetic means that CL targets DNA gyrase in the gram-positive bacterium Streptococcus

172 cient binding, cleavage, and supercoiling by DNA gyrase in vitro.

173 rococci clinical isolates and inhibit mutant DNA gyrase in-vitro.

174 emonstrated that novobiocin, an inhibitor of DNA gyrase, inhibited in vitro DNA replication by preven

175 In DNA gyrase-inhibited cells, the pairing prevented diffus

176 etoposide's antibacterial activity is due to DNA gyrase inhibition and suggests other anticancer agen

177 agents and operate at least in part through DNA gyrase inhibition, leading to the accumulation of si

178 ine whether these moieties are important for DNA gyrase inhibition, these compounds were tested for t

179 toxin activities including RNA scission and DNA gyrase inhibition.

180 hich we have previously demonstrated to be a DNA gyrase inhibitor in vitro, suggesting that ParE1/3 i

181 Simocyclinone D8 (SD8), a potent DNA gyrase inhibitor made by Streptomyces antibioticus,

182 ntrols the export of simocyclinone, a potent DNA gyrase inhibitor made by Streptomyces antibioticus.

183 ase of the former gene, as well as using the DNA gyrase inhibitor novobiocin.

184 Simocyclinone D8 is a potent DNA gyrase inhibitor produced by Streptomyces antibiotic

185 Simocyclinone D8 (SD8) is a potent DNA gyrase inhibitor produced by Streptomyces antibiotic

186 inone C4, which is essentially inactive as a DNA gyrase inhibitor, also induces simX expression in vi

187 7-oxo-SD8 was essentially inactive as a DNA gyrase inhibitor, and the reduction of the keto grou

188 transcription is inhibited by novobiocin, a DNA gyrase inhibitor, at concentrations subinhibitory fo

189 Novobiocin, a known DNA gyrase inhibitor, binds to a nucleotide-binding site

190 Recent studies have shown that the DNA gyrase inhibitor, novobiocin, binds to a previously

191 Development of the DNA gyrase inhibitor, novobiocin, into a selective Hsp90

192 A DNA gyrase inhibitor, novobiocin, was previously shown t

193 The DNA gyrase inhibitor, novobiocin, was recently shown to

194 crocin B17 (MccB17) is a ribosomally encoded DNA-gyrase inhibitor.

195 f AZD0914 upon removal of magnesium from the DNA-gyrase-inhibitor complex.

196 hrombin inhibitors, HIV protease inhibitors, DNA gyrase inhibitors and many others.

197 an smc null mutant was hypersensitive to the DNA gyrase inhibitors coumermycin A1 and norfloxacin.

198 ly, (-)-1 was not cross-resistant with other DNA gyrase inhibitors such as fluoroquinolone and aminoc

199 This novel class of DNA gyrase inhibitors was extensively investigated by va

200 itial hits resulted in low nanomolar E. coli DNA gyrase inhibitors, some of which exhibited micromola

201 this basis we present a model for the AhQnr:DNA gyrase interaction where loop1 interacts with the gy

202 ce factors bind to and disrupt the quinolone-DNA-gyrase interaction is proposed.

203 DNA gyrase introduces negative supercoiling into circula

204 DNA supercoiling by DNA gyrase involves the cleavage of a DNA helix, the pas

205 Supercoiling by DNA gyrase involves the passage of one segment of double

206 t a scheme for the DNA cleavage chemistry of DNA gyrase involving two metal ions.

207 DNA gyrase is a clinically validated target for developi

208 DNA gyrase is a DNA topoisomerase present in bacteria an

209 DNA gyrase is a molecular machine that uses the energy o

210 DNA gyrase is a relatively poor decatenase, catalyzing s

211 DNA gyrase is a remarkable enzyme, catalysing the seemin

212 DNA gyrase is a type II DNA topoisomerase from bacteria

213 Bacterial DNA gyrase is a well-established and validated target fo

214 Bacterial DNA gyrase is a well-known and validated target in the d

215 se ATP during their reactions; however, only DNA gyrase is able to harness the free energy of hydroly

216 DNA gyrase is an essential bacterial enzyme composed of

217 DNA gyrase is an essential bacterial enzyme required for

218 al product antibiotics that target bacterial DNA gyrase is assembled from tyrosine by nonribosomal pe

219 nation and the introduction of supercoils by DNA gyrase is discussed in the context of the simulation

220 the dimerization domain of the B subunit of DNA gyrase is fused to the cytoplasmic domain of VEGFRs

221 Relaxation of negatively supercoiled DNA by DNA gyrase is inhibited, whereas the extent of supercoil

222 ed circular DNA templates in the presence of DNA gyrase is known to stimulate negative DNA supercoili

223 These results suggest that DNA gyrase is the main intracellular target of MccB17.

224 Inhibition of the ATPase activity of DNA gyrase is the mechanism by which coumarin-class anti

225 DNA gyrase is the only topoisomerase able to introduce n

226 DNA gyrase is the only topoisomerase that can introduce

227 DNA gyrase is the only type II topoisomerase in Mycobact

228 When DNA gyrase is trapped on bacterial chromosomes by quinol

229 DNA gyrase is unique among enzymes for its ability to ac

230 DNA gyrase is unique among type II topoisomerases in tha

231 o biochemical methods; i.e., DNA-nicking and DNA-gyrase methods to examine whether certain sequence-s

232 In order to negatively supercoil DNA, gyrase must wrap a length of DNA around itself in a

233 t, the utilization of topoisomerase I and/or DNA gyrase mutants, second, the specific inhibition of D

234 fferent inhibitors of the ATPase activity of DNA gyrase, namely the coumarin antibiotic, novobiocin,

235 The DNA gyrase negative supercoiling mechanism involves the

236 DNA gyrase negatively supercoils DNA in a reaction coupl

237 he synthesis and inhibitory activity against DNA gyrase of a series of diphenic acid monohydroxamides

238 t study has analysed the action of bacterial DNA gyrase on a single substrate DNA molecule, discrimin

239 strains or drugs that specifically inhibited DNA gyrase or bound to DNA directly, thereby affecting c

240 s either by interfering with the activity of DNA gyrase or by facilitating the relaxation reaction.

241 was mostly normal in cells with inactivated DNA gyrase or in mukB-null mutants lacking topA, althoug

242 somerase conflictingly categorized as either DNA gyrase or topo IV.

243 ight inhibit transcription, DNA replication, DNA gyrase or topoisomerase I; however, we found no furt

244 Using strains in which either DNA gyrase or topoisomerase IV, or both, were resistant

245 f both forks required the presence of either DNA gyrase or topoisomerase IV, suggesting that modulati

246 le resulting in an A271E substitution in the DNA gyrase protein generated a strain unable to grow on

247 We show here that in the absence of DNA gyrase, replication fork progression from oriC on a

248 ing catalase-peroxidase and the A subunit of DNA gyrase, respectively.

249 enzyme as relaxed circular DNA treated with DNA gyrase, resulted in the highest levels of ATPase act

250 In Escherichia coli topA strains, DNA gyrase selectively converts the positively supercoil

251 er drug etoposide with Staphylococcus aureus DNA gyrase, showing binding at the same sites in the cle

252 ine-naphthyridine agents, which target novel DNA gyrase sites, other novel quinolones that have high

253 otide internal fragment of the gene encoding DNA gyrase subunit B (GyrB) for VGS species-level identi

254 n reading frame with significant homology to DNA gyrase subunit B (gyrB) of Helicobacter pylori.

255 subsequent adenylylation of its target, the DNA gyrase subunit GyrB.

256 eviously reported experiments, inhibition of DNA gyrase supercoiling activity by wild-type MccB17 als

257 subset of BBZ compounds inhibited S. aureus DNA gyrase supercoiling activity with IC(50) values in t

258 example in which misfolding of one protein, DNA gyrase, suppresses a deficiency of another, topoisom

259 nt N78 are homologous to two key residues of DNA gyrase that affect quinolone sensitivity, we generat

260 l mechanism of action, inhibiting the mutant DNA gyrase that confers FQR.

261 at A. thaliana encodes an organelle-targeted DNA gyrase that is the target of the quinolone drug cipr

262 DNA gyrase, the bacterial enzyme that supercoils DNA, is

263 tenation activity of Topo IV but not that of DNA gyrase, the other type II topoisomerase in the cell.

264 ves quinolone inhibition of Escherichia coli DNA gyrase, thus providing an appropriate model system f

265 de a physical explanation for the ability of DNA gyrase to constrain a positive superhelical DNA wrap

266 perate through both inhibition of binding of DNA gyrase to DNA and accumulation of single-stranded DN

267 ch corresponds to the A subunit of bacterial DNA gyrase, to identify amino acid side chains that augm

268 instance, analog 49c was found to be a dual DNA gyrase-topoisomerase IV inhibitor, with broad antiba

269 mutations in the gyrA and parC genes of the DNA gyrase/topoisomerase IV complex that occurred in the

270 eliminated the protective effect of QnrB1 on DNA gyrase toward inhibition by quinolones, whereas dele

271 DNA gyrase unlinks replicating DNA by introducing negati

272 DNA gyrase uses the energy of ATP hydrolysis to introduc

273 nalysis of high-speed structural dynamics of DNA gyrase using AuRBT revealed an unanticipated transie

274 e have analysed the DNA cleavage reaction of DNA gyrase using oligonucleotides annealed to a single-s

275 The mechanism of inhibition of DNA gyrase was distinct from the fluoroquinolones, as sh

276 rase IV were efficient at this task, whereas DNA gyrase was very inefficient at precatenane removal.

277 in sequence to the GyrA and GyrB subunits of DNA gyrase, we have used DNA sequence analysis to identi

278 ic unit (REP1) of the same RIB element binds DNA gyrase weakly.

279 homology, CT189/190 are the two subunits of DNA gyrase, whereas CT643 is a topoisomerase I.

280 n both parC (DNA topoisomerase IV) and gyrA (DNA gyrase), which were shown previously to confer fluor

281 differ from eukaryotes by having the enzyme DNA gyrase, which catalyses the ATP-dependent negative s

282 The gyrA gene encodes one subunit of DNA gyrase, which is a primary target for fluoroquinolon

283 up interacts directly with the target enzyme DNA gyrase, which is a validated drug target.

284 The C-terminal domain of the A subunit of DNA gyrase, which we term Gac, is naturally synthesized

285 in is a nanomolar inhibitor of the bacterial DNA gyrase with a strong activity against various Gram-n

286 lass of antibacterial thiophenes that target DNA gyrase with a unique mechanism of action and have ac

287 a biochemical analysis of the interaction of DNA gyrase with the Mu SGS, pSC101 and pBR322 sites.